Article Information
History
- August 11, 2023.
Article Versions
- Version 1 (February 6, 2023 - 13:51).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Joanna I. López-Velazco1,*,
- Sara Manzano1,*,
- María Otaño2,
- Kepa Elorriaga2,
- Núria Bultó2,
- Julio Herrero2,
- Ainhara Lahuerta1,2,
- Virginia Segur2,
- Isabel Álvarez-López1,2,
- Maria M. Caffarel1,3,#,† and
- Ander Urruticoechea1,2,#,†
- 1Biodonostia Health Research Institute, San Sebastian, Spain
- 2Gipuzkoa Cancer Unit, OSI Donostialdea - Onkologikoa Foundation, San Sebastian, Spain
- 3IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
- ↵†Corresponding authors:
Dr Maria M. Caffarel, Biodonostia Health Research Institute, Paseo Dr Begiristain s/n, San Sebastian, 20014, Spain. Email: maria.caffarel{at}biodonostia.org, Tel: +34 943328193. // Dr Ander Urruticoechea, Onkologikoa Foundation, Paseo Dr Begiristain 121, San Sebastian, 20014, Spain. Email: anderu{at}onkologikoa.org, Tel: +34 943328400.
Posted August 11, 2023.
A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor positive breast cancer
